| Document Date: 2015-01-14 05:46:19
Open Document File Size: 184,22 KBShare Result on Facebook
Company Vertex Pharmaceuticals / / Country United Kingdom / / Currency GBP / / Event Product Issues / / IndustryTerm estimated carrier rate / organ systems / food resulting / problems digesting food / health technology assessment / treatment of cystic fibrosis / / MedicalCondition infertility / troublesome cough / bronchospasm / repeated chest infections / airway obstruction / disease / respiratory failure / Introduction Cystic fibrosis / CF disease / pulmonary function / airway infection / assessment Cystic Fibrosis / Plain Language Summary Cystic fibrosis / cystic fibrosis CFTR / diabetes / distinct disease / chest infections / pulmonary disease / chronic inflammation / lung disease / treatment cystic fibrosis / osteoporosis / cystic fibrosis transmembrane conductance regulator / repeated infections / male infertility / bronchiectasis / autosomal recessive disorder / Cystic Fibrosis / long-term infection / inflammation / infections / recessively inherited disease / serious infection / / MedicalTreatment enzyme replacement therapy / chest physiotherapy / antibiotics / lung transplants / intravenous therapy / physiotherapy / / Organization NHS England Medical Directorate Specialised Services Skipton House / European Union / NHS / / / Position Author / / Product ibuprofen / Glycine / gene / / Technology GPS / transplantation / / URL www.england.nhs.uk/commissioning / /
SocialTag |
Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (G551D mutation) Reference: NHS England A01/P/a 1